[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA47125A - Dérivés de pyrazole en tant qu'inhibiteurs de malt1 - Google Patents

Dérivés de pyrazole en tant qu'inhibiteurs de malt1

Info

Publication number
MA47125A
MA47125A MA047125A MA47125A MA47125A MA 47125 A MA47125 A MA 47125A MA 047125 A MA047125 A MA 047125A MA 47125 A MA47125 A MA 47125A MA 47125 A MA47125 A MA 47125A
Authority
MA
Morocco
Prior art keywords
pyrazole derivatives
malt1 inhibitors
malt1
inhibitors
pyrazole
Prior art date
Application number
MA047125A
Other languages
English (en)
Inventor
Brett Douglas Allison
Joseph Kent Barbay
Didier Jean-Claude Berthelot
Peter J Connolly
Maxwell David Cummings
Gaston Diels
James Patrick Edwards
Kevin D Kreutter
Tianbao Lu
Ulrike Philippar
Fang Shen
Johannes Wilhelmus John Fitzgerald Thuring
Tongfei Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47125A publication Critical patent/MA47125A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA047125A 2016-12-21 2017-12-20 Dérivés de pyrazole en tant qu'inhibiteurs de malt1 MA47125A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662437384P 2016-12-21 2016-12-21

Publications (1)

Publication Number Publication Date
MA47125A true MA47125A (fr) 2021-04-28

Family

ID=61628454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047125A MA47125A (fr) 2016-12-21 2017-12-20 Dérivés de pyrazole en tant qu'inhibiteurs de malt1

Country Status (23)

Country Link
US (2) US10954214B2 (fr)
EP (1) EP3558969B1 (fr)
JP (1) JP7138641B2 (fr)
KR (1) KR102583317B1 (fr)
CN (1) CN110214136A (fr)
AR (1) AR110421A1 (fr)
AU (2) AU2017382185C1 (fr)
BR (1) BR112019012355A2 (fr)
CA (1) CA3048027A1 (fr)
CL (1) CL2019001709A1 (fr)
CO (1) CO2019006622A2 (fr)
EA (1) EA201991503A1 (fr)
ES (1) ES2992411T3 (fr)
IL (1) IL267343B2 (fr)
MA (1) MA47125A (fr)
MX (2) MX2019007540A (fr)
PE (1) PE20191755A1 (fr)
PH (1) PH12019501212A1 (fr)
TN (1) TN2019000192A1 (fr)
TW (1) TWI795381B (fr)
UA (1) UA127920C2 (fr)
UY (1) UY37537A (fr)
WO (1) WO2018119036A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
DK3377488T3 (da) 2015-11-19 2022-10-03 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
ES2844374T3 (es) 2015-12-22 2021-07-22 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
PE20190731A1 (es) 2016-06-20 2019-05-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
FI3697785T3 (fi) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidatsopyridiiniyhdisteitä pad:n estäjinä
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
LT3704120T (lt) 2017-11-24 2024-06-25 Jubilant Episcribe Llc Heterocikliniai junginiai kaip prmt5 inhibitoriai
CN111770759A (zh) 2017-12-28 2020-10-13 通用医疗公司 靶向cbm信号体复合物诱导调节性t细胞使肿瘤微环境发炎
CA3093527A1 (fr) 2018-03-13 2019-09-19 Jubilant Prodel LLC Composes bicycliques utilises en tant qu'inhibiteurs de l'interaction/activation de pd1/pd-l1
FI3774791T3 (fi) 2018-03-30 2023-03-21 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
US11040031B2 (en) * 2018-06-18 2021-06-22 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
KR20210024002A (ko) * 2018-06-18 2021-03-04 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피라졸 유도체
TW202045008A (zh) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
MX2021010144A (es) * 2019-02-22 2021-09-14 Janssen Pharmaceutica Nv Formulaciones farmaceuticas.
US20220127249A1 (en) 2019-02-22 2022-04-28 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
JP7554768B2 (ja) 2019-04-11 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としての尿素誘導体
WO2021030162A1 (fr) 2019-08-09 2021-02-18 Incyte Corporation Sels d'un inhibiteur de pd-1/pd-l1
PH12022550754A1 (en) 2019-09-30 2023-08-23 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
TW202132288A (zh) * 2019-10-24 2021-09-01 日商小野藥品工業股份有限公司 Ｔｒｅｋ（ｔｗｉｋ相關的ｋ＋通道）通道功能的調節劑
KR20220101664A (ko) 2019-11-11 2022-07-19 인사이트 코포레이션 Pd-1/pd-l1 억제제의 염 및 결정질 형태
CN114981453A (zh) * 2019-11-22 2022-08-30 詹森药业有限公司 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定
KR20220116460A (ko) * 2019-11-22 2022-08-23 얀센 파마슈티카 엔.브이. NF-kB 전좌 분석을 사용하여 MALT1 억제제의 효능을 평가하기 위한 방법
WO2021138298A1 (fr) * 2019-12-30 2021-07-08 Rheos Medicines, Inc. Modulateurs de malt1 et leurs utilisations
WO2021262969A1 (fr) 2020-06-24 2021-12-30 The General Hospital Corporation Matériels et méthodes de traitement du cancer
EP4199908A1 (fr) 2020-08-21 2023-06-28 JANSSEN Pharmaceutica NV Forme amorphe d'un inhibiteur de malt1 et formulations de celui-ci
KR20230054381A (ko) 2020-08-21 2023-04-24 얀센 파마슈티카 엔.브이. Malt1 억제제 및 폴리에틸렌 글리콜과 지방산의 혼합물을 포함하는 약제학적 제형
WO2022099075A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Forme cristalline d'un inhibiteur pd-1/pd-l1
AU2021373044A1 (en) 2020-11-06 2023-06-08 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
WO2022099018A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Procédé de préparation d'un inhibiteur de pd-1/pd-l1
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス，インコーポレーテッド がんを治療する材料及び方法
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2022167962A1 (fr) * 2021-02-04 2022-08-11 Aurigene Discovery Technologies Limited Composés de pyrazolyle substitués utiles en tant qu'inhibiteurs de malt-1
KR20230154227A (ko) 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
AU2022231352A1 (en) * 2021-03-03 2023-10-19 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor
WO2022262855A1 (fr) * 2021-06-18 2022-12-22 上海拓界生物医药科技有限公司 Inhibiteur de malt1, son procédé de préparation et son utilisation
US20240336594A1 (en) * 2021-07-05 2024-10-10 Betta Pharmaceuticals Co., Ltd Six-membered aryl or heteroaryl amides, and composition and use thereof
WO2023016995A1 (fr) 2021-08-09 2023-02-16 Janssen Pharmaceutica Nv Compositions destinées à être utilisées dans le traitement de malignités des lymphocytes b
CN113912511B (zh) * 2021-11-29 2024-02-13 广东广康生化科技股份有限公司 一种联苯肼酯中间体的合成方法
CN118451068A (zh) * 2021-12-30 2024-08-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
WO2023148501A1 (fr) * 2022-02-03 2023-08-10 C4X Discovery Limited Dérivés hétérocycliques en tant qu'inhibiteurs de malt1
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
TW202430031A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
WO2024115512A1 (fr) 2022-11-30 2024-06-06 Syngenta Crop Protection Ag Dérivés de tétrahydroisoquinoline microbiocides
WO2024125628A1 (fr) * 2022-12-16 2024-06-20 江苏恒瑞医药股份有限公司 Promédicament ester de phosphate d'un inhibiteur de malt1
WO2025002333A1 (fr) * 2023-06-29 2025-01-02 上海翰森生物医药科技有限公司 Forme cristalline d'un inhibiteur de dérivé tricyclique et son procédé de préparation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
CA2465207C (fr) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides et -sulfonamides
WO2004098515A2 (fr) * 2003-04-30 2004-11-18 Agensys, Inc. Acides nucleiques et proteines correspondantes appelees 109p1d4 utiles dans le traitement et la detection du cancer
ATE482200T1 (de) 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
US20090156582A1 (en) 2005-02-09 2009-06-18 Tetsuya Tsukamoto Pyrazole Compound
CN100526430C (zh) 2005-10-19 2009-08-12 中国石油化工股份有限公司 一种生产清洁汽油的方法
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7872031B2 (en) 2006-03-22 2011-01-18 Vertex Pharmaceuticals Incorporated c-MET protein kinase inhibitors
WO2008008286A2 (fr) 2006-07-12 2008-01-17 Merck & Co., Inc. Pyrazoles substitués servant d'antagonistes des récepteurs de la ghréline
US8389544B2 (en) 2007-01-17 2013-03-05 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
JP2010520864A (ja) 2007-03-09 2010-06-17 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ヒドロキシステロイドデヒドロゲナーゼインヒビターとしてのインドール−及びベンズイミダゾールアミド類
CN101366715A (zh) 2007-08-15 2009-02-18 上海医药工业研究院 一种雷帕霉素组合物及其制备方法
WO2009065897A2 (fr) 2007-11-21 2009-05-28 Vib Vzw Inhibiteurs de l'activité protéolytiques de malt1 et leurs utilisations
JP5536073B2 (ja) 2008-09-24 2014-07-02 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫を防除するためのピラゾール化合物
WO2010039039A1 (fr) 2008-10-03 2010-04-08 Clavis Pharma Asa Formulations orales de dérivés de gemcitabine
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2011036885A1 (fr) 2009-09-25 2011-03-31 武田薬品工業株式会社 Composé hétérocyclique
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
IL300955A (en) 2010-06-03 2023-04-01 Pharmacyclics Llc (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma
US8716487B2 (en) 2010-06-22 2014-05-06 Basf Se Process for preparing 4-hydroxypyridines
CN103080106A (zh) 2010-07-06 2013-05-01 诺瓦提斯公司 用作激酶抑制剂的环醚化合物
WO2012063896A1 (fr) 2010-11-11 2012-05-18 第一三共株式会社 Nouveau dérivé de pyrazole amide
KR20150020228A (ko) 2012-05-31 2015-02-25 에프. 호프만-라 로슈 아게 아미노퀴나졸린 및 피리도피리미딘 유도체
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
SG11201503642YA (en) 2012-11-09 2015-06-29 Univ Cornell Small molecule inhibitors of malt1
WO2014086478A1 (fr) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibiteurs de la protéase malt1
KR20150103751A (ko) 2013-01-10 2015-09-11 그뤼넨탈 게엠베하 Crac 채널 억제제로서의 피라졸릴계 카복스아미드 ｉ
JP2015096499A (ja) * 2013-10-11 2015-05-21 田辺三菱製薬株式会社 医薬組成物
MX2016015544A (es) 2014-05-28 2017-03-23 Novartis Ag Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1.
WO2015192081A1 (fr) 2014-06-13 2015-12-17 Byrd, John C. Biomarqueur permettant de prédire la réponse d'une llc à un traitement avec un inhibiteur de la btk
WO2016005994A2 (fr) 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Composition pharmaceutique comprenant une dispersion solide de médicaments de classe ii bcs avec gelucires
US9730938B2 (en) 2014-08-08 2017-08-15 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
DK3191449T3 (da) 2014-09-10 2020-08-03 Glaxosmithkline Ip Dev Ltd Forbindelser som ret- (rearranged during transfection) hæmmere
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
WO2016209688A1 (fr) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions destinées au traitement du cancer, et leurs utilisations
HRP20220599T1 (hr) 2015-11-06 2022-06-24 Incyte Corporation Heterociklički spojevi kao inhibitori pi3k-gama
WO2017081641A1 (fr) * 2015-11-13 2017-05-18 Novartis Ag Nouveaux dérivés de pyrazolo-pyrimidine
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
EP3423452A4 (fr) 2016-03-01 2019-10-30 University of Maryland, Baltimore Inhibiteurs de la voie de signalisation wnt pour le traitement de maladies
SG11201900745VA (en) 2016-07-29 2019-02-27 Lupin Ltd Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018103060A1 (fr) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation
CA3046578A1 (fr) 2016-12-21 2018-06-28 Acerta Pharma B.V. Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
KR20190096409A (ko) 2016-12-21 2019-08-19 메레오 바이오파마 3 리미티드 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
WO2018141749A1 (fr) 2017-02-01 2018-08-09 Medivir Ab Applications thérapeutiques d'inhibiteurs de malt1
WO2018165385A1 (fr) 2017-03-08 2018-09-13 Cornell University Inhibiteurs de malt1 et leurs utilisations
WO2018226150A1 (fr) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine utilisés en tant qu'inhibiteurs de malt-1
CN111770759A (zh) 2017-12-28 2020-10-13 通用医疗公司 靶向cbm信号体复合物诱导调节性t细胞使肿瘤微环境发炎
CN111801245B (zh) 2018-02-23 2024-04-30 工业设备运营公司 产生磁场的设备以及对交通工具动态充电的感应式充电系统的初级装置
KR20210024002A (ko) 2018-06-18 2021-03-04 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피라졸 유도체
US11040031B2 (en) 2018-06-18 2021-06-22 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
MX2021010144A (es) 2019-02-22 2021-09-14 Janssen Pharmaceutica Nv Formulaciones farmaceuticas.
US20220127249A1 (en) 2019-02-22 2022-04-28 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
JP7554768B2 (ja) 2019-04-11 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としての尿素誘導体
CN114981453A (zh) 2019-11-22 2022-08-30 詹森药业有限公司 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定
KR20220116460A (ko) 2019-11-22 2022-08-23 얀센 파마슈티카 엔.브이. NF-kB 전좌 분석을 사용하여 MALT1 억제제의 효능을 평가하기 위한 방법
WO2021138298A1 (fr) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Modulateurs de malt1 et leurs utilisations
KR20230054381A (ko) 2020-08-21 2023-04-24 얀센 파마슈티카 엔.브이. Malt1 억제제 및 폴리에틸렌 글리콜과 지방산의 혼합물을 포함하는 약제학적 제형
EP4199908A1 (fr) 2020-08-21 2023-06-28 JANSSEN Pharmaceutica NV Forme amorphe d'un inhibiteur de malt1 et formulations de celui-ci
KR20230154227A (ko) 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
AU2022231352A1 (en) 2021-03-03 2023-10-19 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Also Published As

Publication number Publication date
EA201991503A1 (ru) 2019-11-29
CA3048027A1 (fr) 2018-06-28
JP2020514267A (ja) 2020-05-21
MX2022005827A (es) 2022-06-08
AU2022201352A1 (en) 2022-03-24
TN2019000192A1 (en) 2020-10-05
AR110421A1 (es) 2019-03-27
ES2992411T3 (es) 2024-12-12
US10954214B2 (en) 2021-03-23
AU2017382185A1 (en) 2019-06-13
US20180170909A1 (en) 2018-06-21
AU2017382185C9 (en) 2022-08-04
CO2019006622A2 (es) 2019-06-28
IL267343B2 (en) 2023-06-01
US20220315557A1 (en) 2022-10-06
JP7138641B2 (ja) 2022-09-16
PE20191755A1 (es) 2019-12-12
UY37537A (es) 2018-06-29
KR20190093669A (ko) 2019-08-09
EP3558969B1 (fr) 2024-09-18
KR102583317B1 (ko) 2023-09-27
WO2018119036A1 (fr) 2018-06-28
EP3558969A1 (fr) 2019-10-30
BR112019012355A2 (pt) 2019-11-26
US12077521B2 (en) 2024-09-03
EP3558969C0 (fr) 2024-09-18
TWI795381B (zh) 2023-03-11
TW201835067A (zh) 2018-10-01
CN110214136A (zh) 2019-09-06
MX2019007540A (es) 2019-10-24
UA127920C2 (uk) 2024-02-14
PH12019501212A1 (en) 2019-12-16
CL2019001709A1 (es) 2019-10-04
AU2017382185B2 (en) 2021-12-02
IL267343A (en) 2019-08-29
AU2017382185C1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
ME03776B (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac